Firma QIAGEN N.V., Autor bei PR-Web

QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021

Posted on 4. May 2021 by Firma QIAGEN N.V. Posted in General Tagged cer, cloud, diasorin, lyme, market, qiacube, qiagen, qiagen's, qiasphere, qiastat, quantiferon, securities, statements, with

Q1 2021 net sales rise 52% (48% CER) to $567.2 million, exceeds outlook for at least 45% CER growth; adj. EPS up 94% to $0.66 ($0.65 CER), exceeds outlook for ~$0.60-0.62 CER 16% CER growth to $364 million from non-COVID […]

QIAGEN launches therascreen BRAF test as companion diagnostic to a BRAFTOVI® (encorafenib) based regimen in metastatic colorectal cancer

Posted on 16. April 2020 by Firma QIAGEN N.V. Posted in Research / Development Tagged braf, cancer, cdx, erbitux, new, patients, pcr, qiagen, qiagen's, qiasymphony, rgq, therapy, therascreen, v600e, with

• U.S. FDA approves therascreen BRAF V600E RGQ PCR assay as companion diagnostic • Test will help identify patients eligible for treatment with the BRAF inhibitor, BRAFTOVI, which the FDA has approved for use in combination with ERBITUX® (cetuximab) in […]

QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA Policy

Posted on 24. March 2020 by Firma QIAGEN N.V. Posted in General Tagged currency, eua, influenza, market, patients, qiagen, qiagen's, qiastat, rna, securities, shipments, statements, swabs, with

. • QIAstat-Dx syndromic testing system can differentiate novel coronavirus from 20 other respiratory targets • Requires less than one minute for sample preparation and delivers results in about one hour • Adds an important tool for clinicians as part […]

QIAGEN dramatically ramping up global production capacity for RNA extraction kits for use in detection of SARS-CoV-2 coronavirus

Posted on 18. March 2020 by Firma QIAGEN N.V. Posted in Research / Development Tagged aspr, eua, market, meningitis, qiacube, qiagen, qiagen's, qiastat, qiasymphony, quantiferon, securities, sequencing, statements, with

Goal to reach global capacity for RNA nucleic extraction workflows for over 10 million patient tests a month by end of June 2020 and to reach capacity for 20 million monthly patient tests by end of 2020 Welcomes FDA and […]

QIAGEN gains BARDA funding for approval process of QIAstat-Dx test kit for SARS-CoV-2 coronavirus

Posted on 13. March 2020 by Firma QIAGEN N.V. Posted in Research / Development Tagged aspr, market, meningitis, patients, qiagen, qiagen's, qiastat, qiasymphony, quantiferon, securities, sequencing, statements, syndrome, with

First syndromic testing solution to get U.S. agency’s development support in novel coronavirus response QIAstat-Dx Respiratory SARS-CoV-2 Panel test kit will rapidly differentiate novel coronavirus from 21 other pathogens implicated in respiratory syndromes Further expanding QIAGEN’s global mobilization to […]

Thermo Fisher Scientific to Acquire QIAGEN N.V.

Posted on 3. March 2020 by Firma QIAGEN N.V. Posted in General Tagged forecast, gaap, ppi, qiagen, qiagen's, revenue, rna, securities, statements, tax, thermo, transplant, unity, with, wpg

. Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies Creates significant value and is expected to be immediately accretive to adjusted earnings […]

QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2

Posted on 27. February 2020 by Firma QIAGEN N.V. Posted in Research / Development Tagged clinical, coronavirus, disease, interim, ncov, neumodx, new, pcr, qiagen, qiagen's, qiastat, qiasymphony, respiratory, testing, with

. QIAstat-Dx Respiratory 2019-nCoV Panel rapidly differentiates novel coronavirus from 21 other pathogens implicated in serious respiratory syndromes Panel being tested at four hospitals in China after initial evaluation on clinical samples by a leading Paris hospital Adds to QIAGEN’s […]

QIAGEN builds on global collaboration with Amgen for companion diagnostic development in non-small cell lung cancer

Posted on 14. January 2020 by Firma QIAGEN N.V. Posted in Research / Development Tagged amg, cancer, g12c, market, ngs, qiagen, qiagen's, qiastat, qiasymphony, quantiferon, sequencing, statements, therascreen, with

• QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation • QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA QIAGEN N.V. (NYSE: QGEN; Frankfurt […]

QIAGEN Clinical Insight surpasses 1 million patient test cases analyzed and interpreted

Posted on 20. June 2019 by Firma QIAGEN N.V. Posted in Research / Development Tagged cancer, cloud, exome, genereader, market, ngs, omicsoft, qci, qiagen, qiagen's, qiaseq, sequencing, statements, with

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QIAGEN Clinical Insight (QCI®), its clinical decision support platform for interpretation and reporting of variants derived from analysis of next-generation sequencing (NGS) data, has achieved a milestone of more than […]

QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

Posted on 22. May 2019 by Firma QIAGEN N.V. Posted in Research / Development Tagged bcg, ellume, gold, hiv, market, patients, qft, qiagen, qiagen's, quantiferon, securities, skin, statements, with

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the […]